Marvel Biosciences Announces Grant of Deferred Share Units

Rhea-AI Summary

Marvel Biosciences (MBCOF) announced the award of 35,697 deferred share units (DSUs) to its three independent directors in lieu of cash directors' fees, with all DSUs vesting on October 31, 2026.

Vested DSUs will be settled when a director separates from service and expire 365 days after that separation. The DSUs' deemed value is calculated using the VWAP of $0.21 for the corporation's common shares on the TSX Venture Exchange on October 31, 2025 multiplied by the number of DSUs awarded.

Calgary, Alberta--(Newsfile Corp. - November 10, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 35,697 deferred share units ("DSUs") to Marvel's three independent directors, in lieu of cash payment for directors' fees.

The DSUs will all vest on October 31, 2026. Vested DSUs shall be settled upon the directors' separation from service from the Company and expire 365 days after such directors' separation from service.

The deemed value for the DSUs is calculated using the VWAP of the Corporation's Common Shares on the TSX Venture Exchange on October 31, 2025 being $0.21 multiplied by the number of DSUs awarded.

About Marvel Biosciences Corp.
Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary- based pre-clinical stage pharmaceutical development biotechnology company. The Company is developing MB-204, a novel fluorinated derivative of the approved anti-Parkinson's drug Istradefylline, the only clinically approved adenosine A2a antagonist. A significant and growing body of scientific evidence suggests drugs that block the adenosine A2a receptor, such as MB-204, could be useful in treating other neurological diseases such as autism, depression and Alzheimer's Disease. The Company is actively investigating its potential in addressing other neurodevelopmental disorders, such as Rett Syndrome and Fragile X Syndrome, to expand its therapeutic reach.

Contact Information:
Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273886

FAQ

How many DSUs did Marvel Biosciences (MBCOF) grant on November 10, 2025?

The company granted 35,697 DSUs to its three independent directors.

When do the DSUs granted by Marvel Biosciences (MBCOF) vest?

All DSUs vest on October 31, 2026.

How will Marvel Biosciences (MBCOF) calculate the DSUs' value?

Value is the VWAP $0.21 on the TSX Venture Exchange on October 31, 2025 multiplied by the number of DSUs.

When are vested DSUs from Marvel Biosciences (MBCOF) settled and when do they expire?

Vested DSUs are settled upon a director's separation from service and expire 365 days after that separation.

Why did Marvel Biosciences (MBCOF) issue DSUs to directors instead of cash?

The company issued DSUs in lieu of cash payment for directors' fees as disclosed in the announcement.